Brief: Evofem Completes Enrollment In Evoguard Phase 3 Clinical Trial Of Evo100 For Prevention Of Chlamydia And Gonorrhea In Women
04/03/2022 11:56
March 4 (Reuters) - Evofem Biosciences Inc EVFM.O :
* EVOFEM COMPLETES ENROLLMENT IN EVOGUARD PHASE 3 CLINICAL
TRIAL
OF EVO100 FOR PREVENTION OF CHLAMYDIA AND GONORRHEA IN WOMEN
* EVOFEM BIOSCIENCES INC - U.S. REGULATORY SUBMISSION
PLANNED FOR
FIRST HALF OF 2023
* EVOFEM BIOSCIENCES INC - EVOGUARD REMAINS ON TRACK FOR
TOPLINE
DATA READOUT LATER THIS YEAR
Source text for Eikon: ID:nPn7P2yv5a
Further company coverage: EVFM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Evofem Biosciences
See all newsBrief: Evofem Biosciences Adds Additional Manufacturing Capacity For Phexx To Support Global Growth Strategy
Brief: HUB Cyber Security Expands Into Women's Health With Zero-Cash Acquisition Of Evofem Notes
Evofem Biosciences Q1 sales edge up on higher pricing
Evofem Biosciences Q3 net sales rise
Brief: Evofem Anticipates Approval Of Merger With Aditxt At Upcoming Stockholder Meeting